why choose us

First received: April 07, 2026

Clinical Trial: Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro Study

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Malaria (Plasmodium Falciparum)

Study Type: INTERVENTIONAL


Official Title: Confirmation of Artemisinin Partial Resistance in Plasmodium Falciparum Using WHO Criteria: A Multisite Clinical, Molecular and Phenotypic Study Across Five Sentinel Sites in Ethiopia, 2024-2025

Brief Summary: Artemisinin-based combination therapies (ACTs) are the main treatment for falciparum malaria in Africa.Artemisinin partial resistance (ART-R), characterized by delayed parasite clearance after treatment, has been confirmed in four sub-Saharan African countries.In Ethiopia, molecular surveys have detected the Pfkelch13 R622I mutation associated with ART-R at multiple sites, but no study has yet combined clinical, molecular, and in vitro evidence to confirm ART-R per WHO criteria.This multisite study conducted…

Read more